Clovis Oncology (NASDAQ:CLVS) Given Media Sentiment Score of 0.23

Media coverage about Clovis Oncology (NASDAQ:CLVS) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Clovis Oncology earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.8194867908914 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Receive News & Ratings for Clovis Oncology Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

These are some of the media stories that may have impacted Accern’s rankings:

FY2020 EPS Estimates for Clovis Oncology, Inc. (CLVS) Cut by Analyst (americanbankingnews.com)
Research Analysts Set Expectations for Clovis Oncology, Inc.’s FY2019 Earnings (CLVS) (americanbankingnews.com)
Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : August 4, 2017 (finance.yahoo.com)
Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses – Nasdaq (nasdaq.com)
Clovis Oncology Inc (NASDAQ:CLVS) Institutional Investors Sentiment (topactu.net)

Shares of Clovis Oncology (CLVS) traded up 1.38% during trading on Friday, reaching $78.50. 1,312,623 shares of the company were exchanged. The firm has a 50-day moving average price of $87.51 and a 200-day moving average price of $66.24. Clovis Oncology has a 1-year low of $14.62 and a 1-year high of $99.45. The stock’s market capitalization is $3.50 billion.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.27) by $0.02. The company had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. The business’s revenue for the quarter was down 32.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.07) earnings per share. Equities research analysts predict that Clovis Oncology will post ($5.96) earnings per share for the current fiscal year.

Several research analysts have issued reports on the company. Credit Suisse Group restated an “outperform” rating and set a $74.00 target price on shares of Clovis Oncology in a research report on Tuesday, April 18th. Cann assumed coverage on Clovis Oncology in a research report on Thursday, June 22nd. They set a “market perform” rating for the company. Bank of America Corporation restated a “buy” rating on shares of Clovis Oncology in a research report on Thursday. BidaskClub upgraded Clovis Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Finally, Zacks Investment Research lowered Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Clovis Oncology has a consensus rating of “Buy” and a consensus target price of $81.59.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was reported by [[site]] and is the sole property of of [[site]]. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at [[permalink]].

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $91.56, for a total transaction of $274,680.00. Following the sale, the insider now directly owns 197,583 shares in the company, valued at approximately $18,090,699.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders have sold 9,000 shares of company stock worth $602,310. 17.40% of the stock is owned by company insiders.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.